Quality and Regulatory
In order to meet the Regulatory and Quality needs of PathoQuest’s biopharmaceutical customers, the company has implemented a quality program designed to address quality requirements as defined in detail within Chapter 6 (Quality Control) of the European Good Manufacturing Practice for Medicinal Products for Human and the Veterinary Use (E.U. CGMP) and in Current Good Manufacturing Practices 21 CFR Parts 210 and 211 (U.S. CGMP). Next-Generation Sequencing (NGS) is now referenced in newer guidelines, European Pharmacopeia (published January 2018). In line with the above, PathoQuest provides validated next-generation sequencing (NGS) testing solutions following these requirements.
PathoQuest has also received Propel Certification from Illumina after successfully completing the requirements for achieving this recognition. This included demonstrating the ability to produce high-quality data on the NexSeq System following a streamlined and rigorous process. PathoQuest’s Propel Certification is valid for the company’s Biologics Genomic Service projects which utilize Illumina’s NGS library preparation and sequencing protocols.
In addition to the above and in order to meet both customer demands and regulatory requirements, PathoQuest Paris-based facility is the first one in France to obtain the Good Laboratory Practices (GLP) certificate for advanced NGS viral safety testing (“high-throughput sequencing detection of incidental replicative virus test in eukaryote cells”.) PathoQuest uses an overall quality management approach which aligns with ISO 9001:2015. The principles of GLP the company follows are based on Directive 2004/9/EC which is intended to ensure and promote the safety, consistency, high quality, and reliability of chemicals which are used in the process of non-clinical and laboratory testing conducted for non-clinical health and environmental safety studies.
Click here to learn more about PathoQuest’s Biologics Genomic Service for biopharmaceutical companies.